Nitroxoline is a novel inhibitor of NLRP3-dependent pyroptosis.

ABSTRACT: Aberrant activity of the NLR family pyrin domain containing 3 (NLRP3) inflammasome contributes to a wide range of diseases associated with acute inflammatory responses and chronic sterile inflammation. Activation of the NLRP3 inflammasome mediates pyroptotic cell death and the release of pro-inflammatory cytokines. To date, no selective inhibitor of inflammasome activity is available for the use in humans. We conducted a medium-throughput screening of 6280 drugs or drug-like compounds and identified novel inhibitors of the NLRP3 inflammasome. Among these, nitroxoline was further characterized because the drug is approved for antibiotic treatment in humans, and we found no toxicity over a wide range of concentrations. Treatment of THP-1 monocytes with 80 μM nitroxoline markedly reduced the

SUBMITTER: Maeder C 

PROVIDER: S-EPMC12368067 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature